Ajai Chari, MD, is an expert in hematologic oncology who cares for patients at University of California San Francisco Health.
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Advancing MM Care Through Innovation and Equity: Ajai Chari, MD
Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM).
Optimizing Patient Selection for CAR T, Bispecifics Mitigates Adverse Events in High-Risk MM
For higher-risk multiple myeloma (MM), successful patient selection and monitoring strategies are vital for the management of adverse events and the disease itself.
Making Bispecific Therapies Work in Community Settings
Ajai Chari, MD, stresses the importance of making bispecific therapies more accessible at the community level to improve outcomes in multiple myeloma.
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.